Skip to main content

Advertisement

SpringerLink
Log in

Adalimumab therapy—a double-edged sword?

  • Letter to the Editor
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  2. Kozloff M, Cohn A, Christiansen N et al (2005) Safety of bevacizumab (BV) among patients (pts) receiving firstline chemotherapy (CT) for metastatic colorectal cancer (mCRC): preliminary results from a larger registry in the U.S. J Clin Oncol 23:3566

    Google Scholar 

  3. Heinzerling JH, Huerta S (2006) Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 63:334–337

    Article  PubMed  Google Scholar 

  4. Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, van Vollenhoven RF (2004) Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 63:1075–1078

    Article  PubMed  CAS  Google Scholar 

  5. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232–1239

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Colo-rectal Surgery, Cork University Hospital, Wilton, Cork, Ireland

    Donal Peter O’Leary, Eddie Myers & William O. Kirwan

  2. Department of Pathology, Cork University Hospital, Wilton, Cork, Ireland

    Sarah Moran & Tara-Jane Browne

  3. Department of Rheumatology, Cork University Hospital, Wilton, Cork, Ireland

    Sinead Harney

Authors
  1. Donal Peter O’Leary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eddie Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah Moran
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tara-Jane Browne
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sinead Harney
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. William O. Kirwan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donal Peter O’Leary.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O’Leary, D.P., Myers, E., Moran, S. et al. Adalimumab therapy—a double-edged sword?. Int J Colorectal Dis 26, 1621–1623 (2011). https://doi.org/10.1007/s00384-010-1114-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-010-1114-3

Keywords

Search

Navigation